inPractice® - Atypical Antipsychotics and Antiretrovirals

Authors: Amanda H. Corbett, PharmD, BCPS, FCCP; Colin I. Sheffield, PharmD (More Info)
Section Editor: Eric S. Daar, MD
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 6/1/18 (What's New)

Atypical antipsychotics are all CYP substrates and inhibitors
Patients receiving concomitant atypical antipsychotics and antiretrovirals should be closely monitored for response and/or antipsychotic adverse effects
Perphenazine or risperidone should be started at a low dose in patients receiving cobicistat/elvitegravir/emtricitabine/tenofovir DF, cobicistat/elvitegravir/emtricitabine/tenofovir AF, atazanavir/cobicistat, or darunavir/cobicistat with the neuroleptic dose reduced if necessary^{[DHHS ART; FDA COBI/EVG/TDF/FTC; FDA COBI/EVG/TAF/FTC; FDA Atazanavir/Cobicistat; FDA Darunavir/Cobicistat]}